Brief: Shanghai Henlius Biotech Says Application For Phase 1B/2 Clinical Trial Of Hlx43- For Injection In- Combination With Hansizhuang Approved By NMPA
10/01/2025 15:43
Jan 10 (Reuters) - Shanghai Henlius Biotech Inc
2696.HK :
* APPLICATION FOR PHASE 1B/2 CLINICAL TRIAL OF HLX43- FOR
INJECTION IN- COMBINATION WITH HANSIZHUANG APPROVED BY NMPA
Further company coverage: 2696.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln